Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This will be an open-label, non-randomized trial pilot phase II trial open to patients with
myelodysplastic syndrome. The purpose of the study is to find out if the combination of
decitabine, arsenic trioxide and ascorbic acid is safe.